FILING ANALYSIS · MONDAY, NOVEMBER 16

Iambic Therapeutics, Inc. IAM — 8-K: Results of Operations and Financial Condition

positive

Iambic Therapeutics reported strong Q3 financial results, including $24 million in collaboration revenue and a cash position of $252 million, with a pro-forma cash position of $455 million after their IPO and AbbVie upfront payments. The company also announced positive clinical data for its IAM1363 candidate and plans to initiate a registrational study in 2027.

The filing

8-K - Iambic Therapeutics, Inc. (0001997038) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+